PursueCare

The short picture on PursueCare (Middletown, CT): The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The longer picture — clinical framework, payer mix, outcomes — takes a few specific questions to surface.

Care levels at PursueCare

The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The practical question is whether it is genuinely strong at each level, or whether one level is the core business and the others are secondary. The gap between "this facility offers residential" and "residential is the right level for this patient" is wider than most facility websites suggest. Bridge it with an outside assessment before committing.

Insurance and payment

PursueCare accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Most post-treatment billing disputes trace back to a specific moment when an admissions counselor said one thing and the benefits department later documented something else. Avoid the moment by getting the written VOB before admission, not after.

Specialty programming

The facility's documented specialty programming includes: Adult women, Pregnant/postpartum women, Adult men. "Specialty track" is a marketing category often; it becomes a clinical category when specific clinicians deliver specific programming for a documented number of hours per week. Ask for those specifics.

Before you call

Questions that matter before admitting to PursueCare: ASAM level of care (not the facility's category, the clinical level); written VOB; MAT policy. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation. The ones who answer those quickly are usually the ones worth considering. The ones who dodge are almost always worth skipping.